What Is NAD+ IV Therapy

NAD+ IV therapy is the intravenous administration of nicotinamide adenine dinucleotide, a coenzyme required by every living cell for energy metabolism, DNA repair, and signaling functions. The infusion delivers NAD+ directly into the bloodstream, bypassing gastrointestinal absorption and first-pass liver metabolism. It is offered at longevity clinics and integrative medicine practices, typically as a multi-hour drip at doses ranging from 250 mg to 1,000 mg or more per session.

NAD+ levels decline measurably with age. This decline is implicated in reduced mitochondrial function, impaired DNA repair capacity, dysregulated sirtuin activity, and increased vulnerability to metabolic disease. Because NAD+ sits at the intersection of so many age-related processes, restoring its availability has become a central focus in longevity research.

The rationale for IV delivery specifically is pharmacokinetic: oral NAD+ is largely degraded in the gut, and even its precursors (NMN, NR) undergo conversion steps that may limit how much NAD+ ultimately reaches tissues. Intravenous infusion achieves plasma NAD+ concentrations that oral routes cannot match acutely. Whether these transient spikes produce durable intracellular benefits is the key unanswered question, but the biological logic for wanting to replenish a coenzyme this fundamental is well grounded.

NAD+ participates in over 500 enzymatic reactions. Its core function is shuttling electrons during oxidative phosphorylation, the process by which mitochondria generate ATP. Without adequate NAD+, the electron transport chain slows, ATP output drops, and cells shift toward less efficient glycolytic metabolism. By delivering exogenous NAD+ intravenously, the therapy aims to restore the substrate pool that mitochondria depend on for energy production.

Beyond energy metabolism, NAD+ serves as a consumed substrate for three major enzyme families: sirtuins, PARPs (poly ADP-ribose polymerases), and CD38. Sirtuins regulate gene expression, inflammation, and stress resistance; they require NAD+ to deacetylate their targets. PARPs use NAD+ to repair single-strand DNA breaks. CD38, an ectoenzyme that increases with age, degrades NAD+ as part of immune signaling. Because these enzymes consume NAD+ rather than merely borrowing it, the molecule must be continuously replenished. Age-related increases in CD38 activity and chronic DNA damage accelerate NAD+ depletion, creating a supply problem that IV therapy attempts to address directly.

Once infused, NAD+ circulates in plasma, but its entry into cells is not straightforward. Intact NAD+ does not easily cross cell membranes due to its size and charge. Current evidence suggests the molecule is partially degraded extracellularly into nicotinamide and other intermediates, which cells then import and use to resynthesize NAD+ internally via the salvage pathway. This means the IV route may function partly as a high-dose precursor delivery system rather than a direct NAD+ replacement, though the pharmacokinetics are still being characterized.

Human research on NAD+ IV therapy specifically is limited compared to the broader body of work on NAD+ biology and oral precursors. Small open-label studies and case series have documented acute increases in blood NAD+ following infusion, along with participant-reported improvements in energy and cognition. However, large randomized controlled trials evaluating clinical endpoints such as disease incidence, functional capacity, or biological age markers are absent. Most of the mechanistic rationale is extrapolated from preclinical studies in mice, where NAD+ repletion via various routes has shown improvements in mitochondrial function, insulin sensitivity, neurodegeneration markers, and lifespan in certain strains.

The oral precursor literature is more developed. Multiple human trials on NR and NMN have confirmed that these compounds raise blood NAD+ levels, though translating elevated blood NAD+ into measurable health outcomes has proven difficult so far. The IV route adds a layer of complexity: it achieves higher peak levels but with uncertain tissue distribution and duration. A key gap is the lack of head-to-head comparisons between IV NAD+ and oral precursors at equivalent or optimized doses. Until such data exist, the clinical advantage of IV delivery over consistent oral supplementation remains theoretical.

Acute side effects during infusion are common and include nausea, abdominal cramping, chest tightness, and flushing, most of which are dose-rate dependent and resolve when the drip is slowed. Vein irritation and bruising at the infusion site are typical of any IV procedure. Infection risk exists whenever intravenous access is used, making provider sterility standards relevant. The cost is substantial, often several hundred to over a thousand dollars per session, which is not covered by insurance. Long-term safety data from controlled trials does not exist, and the possibility that supraphysiological NAD+ levels could fuel unwanted cellular proliferation (relevant in the context of undiagnosed malignancy) has been raised in theoretical discussions though not confirmed in human studies.